5-alpha Reductase Inhibitors
"5-alpha Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
| Descriptor ID |
D058891
|
| MeSH Number(s) |
D27.505.519.389.870.200 D27.505.696.399.450.855.200
|
| Concept/Terms |
5-alpha Reductase Inhibitors- 5-alpha Reductase Inhibitors
- 5 alpha Reductase Inhibitors
- Inhibitors, 5-alpha Reductase
- Reductase Inhibitors, 5-alpha
- Steroid 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Steroid
- Inhibitors, Steroid 5-alpha-Reductase
- Steroid 5 alpha Reductase Inhibitors
- Testosterone 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Testosterone
- Inhibitors, Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase Inhibitors
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors
- 4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid
- Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "5-alpha Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "5-alpha Reductase Inhibitors".
This graph shows the total number of publications written about "5-alpha Reductase Inhibitors" by people in this website by year, and whether "5-alpha Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "5-alpha Reductase Inhibitors" by people in Profiles.
-
MRI characterization of the dynamic effects of 5a-reductase inhibitors on prostate zonal volumes. Can J Urol. 2013 Dec; 20(6):7002-7.
-
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 2004 May; 45(5):620-6; discussion 626-7.
-
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003 Aug; 92(3):262-6.